DK1641456T3 - Gaboxadol til behandling af depression og andre affektive lidelser - Google Patents
Gaboxadol til behandling af depression og andre affektive lidelserInfo
- Publication number
- DK1641456T3 DK1641456T3 DK04738956.4T DK04738956T DK1641456T3 DK 1641456 T3 DK1641456 T3 DK 1641456T3 DK 04738956 T DK04738956 T DK 04738956T DK 1641456 T3 DK1641456 T3 DK 1641456T3
- Authority
- DK
- Denmark
- Prior art keywords
- gaboxadol
- depression
- treatment
- affective disorders
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US48301903P | 2003-06-25 | 2003-06-25 | |
DKPA200300956 | 2003-06-25 | ||
US53512304P | 2004-01-07 | 2004-01-07 | |
DKPA200400016 | 2004-01-07 | ||
PCT/DK2004/000459 WO2004112786A2 (en) | 2003-06-25 | 2004-06-25 | Gaboxadol for treating depression and other affective disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1641456T3 true DK1641456T3 (da) | 2010-06-21 |
Family
ID=33545397
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK04738956.4T DK1641456T3 (da) | 2003-06-25 | 2004-06-25 | Gaboxadol til behandling af depression og andre affektive lidelser |
Country Status (17)
Country | Link |
---|---|
EP (2) | EP1641456B1 (da) |
JP (1) | JP2007508236A (da) |
AT (1) | ATE459353T1 (da) |
AU (1) | AU2004248890A1 (da) |
BR (1) | BRPI0410857A (da) |
CY (1) | CY1110046T1 (da) |
DE (1) | DE602004025808D1 (da) |
DK (1) | DK1641456T3 (da) |
ES (1) | ES2341004T3 (da) |
HR (1) | HRP20100276T1 (da) |
IL (2) | IL172631A0 (da) |
MX (1) | MXPA05013016A (da) |
NZ (1) | NZ543586A (da) |
PL (1) | PL1641456T3 (da) |
PT (1) | PT1641456E (da) |
SI (1) | SI1641456T1 (da) |
WO (1) | WO2004112786A2 (da) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1663218A1 (en) * | 2003-09-10 | 2006-06-07 | MERCK SHARP & DOHME LTD. | Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome |
WO2005060968A1 (en) | 2003-12-11 | 2005-07-07 | Sepracor Inc. | Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression |
GB0402118D0 (en) * | 2004-01-30 | 2004-03-03 | Merck Sharp & Dohme | Polymorphic forms of a GABAA agonist |
DK1742624T3 (da) | 2004-02-18 | 2010-03-08 | Sepracor Inc | Dopamin-agonist-kombinationsterapi med sedativer til forbedring af søvnkvalitet |
GB0417558D0 (en) * | 2004-08-06 | 2004-09-08 | Merck Sharp & Dohme | Novel combination therapy |
WO2006083682A2 (en) * | 2005-01-28 | 2006-08-10 | H.Lundbeck A/S | Polymorphic forms of a gabaa agonist |
US20080262029A1 (en) * | 2005-04-29 | 2008-10-23 | H. Lundbeck A/S | Acid and Base Salt Forms of Gaboxadol |
TW200920358A (en) * | 2007-08-13 | 2009-05-16 | Lundbeck & Co As H | Method of treating stress-mediated depression |
US20090143335A1 (en) * | 2007-10-29 | 2009-06-04 | H. Lundbeck A/S | Modified absorption formulation of gaboxadol |
CA2732636A1 (en) * | 2008-09-01 | 2009-05-07 | H. Lundbeck A/S | Pharmaceutical composition comprising gaboxadol and an inhibitor of pat1 or oat |
ES2781978T3 (es) | 2015-03-24 | 2020-09-09 | H Lundbeck As | Fabricación de 4,5,6,7-tetrahidroisozaxolo[5,4-c]piridin-3-ol |
MX2019005779A (es) * | 2016-11-22 | 2019-08-22 | Ovid Therapeutics Inc | Metodos para tratar trastornos del desarrollo y/o trastornos convulsivos con flupirtina. |
US20180338959A1 (en) * | 2017-05-24 | 2018-11-29 | Ovid Therapeutics Inc. | Treatment of depressive disorders |
CA3095682A1 (en) * | 2018-04-06 | 2019-10-10 | Ovid Therapeutics Inc. | Use of gaboxadol in the treatment of substance use disorders |
CN112930182A (zh) | 2018-09-20 | 2021-06-08 | 奥维德医疗公司 | 加波沙朵用于治疗图雷特综合征、抽搐和口吃的用途 |
AU2019384561A1 (en) * | 2018-11-21 | 2021-06-10 | Certego Therapeutics Inc. | Combination of gaboxadol and lithium for the treatment of psychiatric disorders |
CN113395962A (zh) | 2018-11-21 | 2021-09-14 | Certego治疗公司 | 加波沙朵用于降低自杀风险和快速缓解抑郁症 |
CN113423399A (zh) | 2018-12-17 | 2021-09-21 | 奥维德医疗公司 | 加波沙朵用于治疗非24小时睡眠-觉醒障碍的用途 |
US11364228B2 (en) | 2019-12-18 | 2022-06-21 | Ovid Therapeutics Inc. | Gaboxadol for therapeutic treatment of 1p36 deletion syndrome |
AU2021275863A1 (en) | 2020-05-20 | 2023-02-02 | Certego Therapeutics Inc. | Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK270378A (da) | 1977-06-20 | 1978-12-21 | Krogsgaard Larsen P | Isoxazolderivater |
DE19525598C2 (de) | 1995-07-13 | 1997-09-25 | Max Planck Gesellschaft | Schlafmittel |
AR031473A1 (es) * | 2000-11-20 | 2003-09-24 | Lundbeck & Co As H | Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide |
US20020165217A1 (en) * | 2001-05-01 | 2002-11-07 | Pfizer Inc. | Combination treatment for anxiety and depression |
KR20030097890A (ko) | 2001-05-21 | 2003-12-31 | 하. 룬트벡 아크티에 셀스카브 | 가복사돌의 과립 제제 |
-
2004
- 2004-06-25 DE DE602004025808T patent/DE602004025808D1/de active Active
- 2004-06-25 ES ES04738956T patent/ES2341004T3/es active Active
- 2004-06-25 BR BRPI0410857-4A patent/BRPI0410857A/pt not_active IP Right Cessation
- 2004-06-25 DK DK04738956.4T patent/DK1641456T3/da active
- 2004-06-25 EP EP04738956A patent/EP1641456B1/en active Active
- 2004-06-25 MX MXPA05013016A patent/MXPA05013016A/es active IP Right Grant
- 2004-06-25 PL PL04738956T patent/PL1641456T3/pl unknown
- 2004-06-25 AT AT04738956T patent/ATE459353T1/de not_active IP Right Cessation
- 2004-06-25 JP JP2006515735A patent/JP2007508236A/ja active Pending
- 2004-06-25 NZ NZ543586A patent/NZ543586A/en unknown
- 2004-06-25 WO PCT/DK2004/000459 patent/WO2004112786A2/en active Application Filing
- 2004-06-25 AU AU2004248890A patent/AU2004248890A1/en not_active Abandoned
- 2004-06-25 PT PT04738956T patent/PT1641456E/pt unknown
- 2004-06-25 EP EP09173892A patent/EP2145620A3/en not_active Withdrawn
- 2004-06-25 SI SI200431414T patent/SI1641456T1/sl unknown
-
2005
- 2005-12-15 IL IL172631A patent/IL172631A0/en unknown
-
2009
- 2009-11-12 IL IL202106A patent/IL202106A0/en unknown
-
2010
- 2010-05-14 CY CY20101100433T patent/CY1110046T1/el unknown
- 2010-05-18 HR HR20100276T patent/HRP20100276T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
PL1641456T3 (pl) | 2010-08-31 |
ATE459353T1 (de) | 2010-03-15 |
JP2007508236A (ja) | 2007-04-05 |
NZ543586A (en) | 2009-07-31 |
BRPI0410857A (pt) | 2006-07-04 |
CY1110046T1 (el) | 2015-01-14 |
EP1641456A2 (en) | 2006-04-05 |
IL202106A0 (en) | 2010-06-16 |
SI1641456T1 (sl) | 2010-06-30 |
MXPA05013016A (es) | 2006-03-02 |
WO2004112786A3 (en) | 2005-04-14 |
EP2145620A2 (en) | 2010-01-20 |
PT1641456E (pt) | 2010-06-01 |
EP2145620A3 (en) | 2010-03-17 |
EP1641456B1 (en) | 2010-03-03 |
DE602004025808D1 (de) | 2010-04-15 |
AU2004248890A1 (en) | 2004-12-29 |
IL172631A0 (en) | 2006-04-10 |
HRP20100276T1 (hr) | 2010-06-30 |
ES2341004T3 (es) | 2010-06-14 |
WO2004112786A2 (en) | 2004-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1641456T3 (da) | Gaboxadol til behandling af depression og andre affektive lidelser | |
EA201370208A1 (ru) | Формы рифаксимина и их применение | |
NO20074943L (no) | Roflumilast for behandlingen av diabetes mellitus | |
EA200601552A1 (ru) | Замещенные конденсированные гетероциклические с-гликозиды | |
EA201001847A1 (ru) | Соединения и композиции, применяемые для лечения малярии | |
EA200901078A1 (ru) | Конъюгаты синтетических агонистов tlr и их применение | |
BRPI0606112A2 (pt) | 3 - heteroaril - 3 - hidróxi - 2 - amino - propil aminas e compostos relacionados, bem como uso dos mesmos e composição farmacêutica | |
DK1888094T3 (da) | Amylin og amylinagonister til behandling af psykiatriske sygdomme og forstyrrelser | |
HN2006000971A (es) | Metodos para preparar composiciones o formas de dosificacion que comprenden un agonista grp119 que tiene el efecto de un secretagogo glp-1 | |
CY1110965T1 (el) | Επιπροσθετες ετεροπολυκυκλικες ενωσεις και η χρηση τους ως ανταγωνιστες μεταβολοτροπικου υποδοχεα γλουταμικου | |
EA200701995A1 (ru) | Способы уменьшения кальцификации | |
DE602004032522D1 (de) | Mit n-alkylhydroxamsäuren substituierte isoindolylverbindungen und deren pharmazeutische verwendung | |
CY1109916T1 (el) | Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις | |
EA200802072A1 (ru) | Ликопин для лечения нарушения обмена веществ | |
CL2008000202A1 (es) | Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor. | |
DE602006017574D1 (de) | Als protein-kinase-inhibitoren nutzbare benzimidazole | |
CL2008003231A1 (es) | Compuestos derivados de 1,3-dihidro-5-isobenzofurancarbonitrilo sustituido, inhibidores selectivos de la recaptacion de serotonina; composicion farmaceutica; procedimiento de preparacion; utiles en el tratamiento y/o prevencion de la eyaculacion prematura. | |
EA200602180A1 (ru) | Производные 2-(1h-индолилсульфанил)ариламина для применения при лечении аффективных расстройств, боли, нгдв и стрессового недержания мочи | |
DE602006008788D1 (de) | Verbindungen | |
ATE471320T1 (de) | 4-aminopiperidinderivate als inhibitoren der monoamin-aufnahme | |
UA90656C2 (ru) | Габоксадол для лечения депрессии | |
NO20060229L (no) | Gaboxadol for behandling av depresjon og andre affektive lidelser | |
DK1523985T3 (da) | Ikke-radioaktivt strontiumholdigt middel til behandling af kræft | |
EA200600945A1 (ru) | Производные морфолина в качестве ингибиторов повторного захвата норадреналина | |
CL2009001113A1 (es) | Compuestos derivados de 4,5-diarilpirrol-2-carboxamida; procedimiento de preparacion de estos; composicion farmaceutica que los comprende; uso en el tratamiento y/o prevencion de trastornos psiquiatricos, dependencia a sustancias, entre otras. |